Reply to: "Challenges and issues in bivariate endpoints in study designs of translational medicine"

Affiliations

¹ Translational Immunology Institute (TII), SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore.
² Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore.
³ Translational Immunology Institute (TII), SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore. Electronic address: valerie.chew@duke-nus.edu.sg.

Comment

Samuel Chuah et al. J Hepatol. 2022 Dec.

. 2022 Dec;77(6):1727-1728.

doi: 10.1016/j.jhep.2022.08.017. Epub 2022 Aug 24.

¹ Translational Immunology Institute (TII), SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore.
² Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610, Singapore.
³ Translational Immunology Institute (TII), SingHealth Duke-NUS Academic Medical Centre, Singapore 169856, Singapore. Electronic address: valerie.chew@duke-nus.edu.sg.

No abstract available

Conflict of interest statement

Conflict of interest All authors declared no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Chuah S, Lee J, Song Y, Kim HD, Wasser M, Kaya NA, Bang K, Lee YJ, Jeon SH, Suthen S, A'Azman S, Gien G, Lim CJ, Chua C, Hazirah SN, Lee HK, Lim JQ, Lim TKH, Yeong J, Chen J, Shin EC, Albani S, Zhai W, Yoo C, Liu H, Choo SP, Tai D, Chew V. Chuah S, et al. J Hepatol. 2022 Sep;77(3):683-694. doi: 10.1016/j.jhep.2022.03.039. Epub 2022 Apr 15. J Hepatol. 2022. PMID: 35430299
Challenges and issues in bivariate endpoints in study designs of translational medicine.
Zhou Q. Zhou Q. J Hepatol. 2022 Dec;77(6):1726-1727. doi: 10.1016/j.jhep.2022.05.035. Epub 2022 Jun 13. J Hepatol. 2022. PMID: 35710037 No abstract available.